Tradipitant: A Novel NK-1 Receptor Antagonist for the Management of Motion Sickness- A New Era in Drug Development. International Journal of Research in Pharmaceutical Sciences and Technology, [S. l.], v. 9, n. 3, 2026. DOI: 10.33974/xxyc9n51. Disponível em: http://rubatosisjournals.com/index.php/ijrpst/article/view/444. Acesso em: 10 aug. 2026.